risk management

McKesson Corp. has announced its agreement to acquire a controlling stake in Community Oncology Revitalization Enterprise Ventures LLC (Core Ventures) for $2.49 billion in cash. Core Ventures, a business and administrative services organization established by Florida Cancer Specialists & Research Institute (FCS), supports nearly 100 FCS clinics across Florida. The transaction will give McKesson approximately 70% ownership, with FCS physicians retaining a minority interest. Core Ventures offers operational and advisory services that align practice locations, ancillary services, and patient care across FCS. The acquisition will integrate Core Ventures into McKesson’s Oncology platform, with financials reported under the US Pharmaceutical segment. FCS, which operates with more than 250 physicians and 280 advanced practice providers, will remain independently owned but will join McKesson’s US Oncology Network, enhancing community-based cancer care. “This acquisition strengthens our ability to deliver advanced treatments and enhance care experiences while reducing costs,” said Brian Tyler, CEO of McKesson. “Our collaboration with FCS and Core Ventures aligns with our commitment to improving patient outcomes and expanding access to quality care.” FCS CEO Nathan Walcker echoed the sentiment: “This partnership with McKesson and joining The US Oncology Network is a significant step for FCS. It enhances our mission to deliver patient-centered cancer care and bring cutting-edge medicine into communities across Florida.” The deal is subject to regulatory clearances and standard closing conditions. Source: hcinnovationgroup